Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02621333Phase 2Terminated

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Role: collaborator

NCT03406832Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Role: collaborator

NCT03406819Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Role: collaborator

NCT01614548Completed

Management of Prostate Cancer in Central China

Role: collaborator

All 4 trials loaded